• Medicine
  • 22 April
  • FDA to approve Grace Therapeutics' GTx-104
    2
  • FDA to approve Sanofi's Subcutaneous Sarclisa
    2
  • 26 April
  • FDA to approve Sanofi's Dupixent
    2
  • 27 April
  • FDA to approve Merck's Doravirine/Islatravir
    2
  • 28 April
  • FDA to approve Sanofi's Tzield
    2
  • 29 April
  • FDA to approve AstraZeneca's Camizestrant
    2
  • FDA to approve AstraZeneca's Truqap (capivasertib)
    2
  • FDA to approve Axsome Therapeutics AXS-05
    2
  • 30 December
  • CDC to issue Level 3 warning by December 31
    2
  • CDC to issue Level 4 warning by December 31
    2